Acute Demyelinating Relapse Management
Acute Demyelinating Relapse Management is a clinical intervention strategy within neuroinflammatory disorder pharmacotherapy that specifically addresses the rapid suppression of immune-mediated demyelination during acute relapses through targeted immunomodulatory or immunosuppressive therapies.
25
Publications
1.9K
Citations
176
Authors
87
Institutions
Publications per year
2017–2026
4
25
Randomized multicenter trial of natalizumab in acute MS relapses
P. O’Connor, Andrew Goodman, A. Willmer–Hulme et al. · Neurology · 2004 · 168 citations
Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS
Alan J. Thompson, C. Kennard, Michael Swash et al. · Neurology · 1989 · 129 citations
Pharmacy, Neurology, Pharmacotherapy +14
1–5 of 25
176
2
h-index
2
h-index
1
h-index
1
h-index
1
h-index
1–5 of 176
87

Johns Hopkins University
Baltimore, United States
2 h-index
6 publications
994 citations
Cleveland Clinic
Cleveland, United States
2 h-index
2 publications
410 citations
Mayo Clinic in Arizona
Scottsdale, United States
2 h-index
5 publications
165 citations
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
1 h-index
3 publications
39 citations
National University of Singapore
Singapore, Singapore
1 h-index
3 publications
138 citations

University of Campania "Luigi Vanvitelli"
Caserta, Italy
1 h-index
2 publications
90 citations

University of Göttingen
Göttingen, Germany
1 h-index
4 publications
156 citations
Danbury Hospital
Danbury, United States
1 h-index
1 publications
33 citations
1–8 of 87
5 publications · 529 citations
5
h-index
2 publications · 101 citations
2
h-index
JNI · 2 publications · 125 citations
2
h-index
2 publications · 340 citations
2
h-index
1 publications · 86 citations
1
h-index
1–5